
Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – Stock analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a note issued to investors on Wednesday, November 18th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of $0.49 per share for the year, up from their prior forecast of $0.29. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2026 earnings at $0.21 EPS, Q1 2027 earnings at $0.24 EPS, Q2 2027 earnings at $0.33 EPS and FY2027 earnings at $1.43 EPS.
Fennec Pharmaceuticals Stock Performance
Shares of FRX stock opened at C$19.29 on Friday. The stock has a market cap of C$681.03 million, a price-to-earnings ratio of 643.00 and a beta of 3.90. The stock has a 50-day moving average of C$15.15 and a 200-day moving average of C$13.24. Fennec Pharmaceuticals has a 1-year low of C$7.59 and a 1-year high of C$19.84.
Insider Buying and Selling
Hedge Funds Weigh In On Fennec Pharmaceuticals
An institutional investor recently bought a new stake in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. purchased a new stake in Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned about 0.30% of Fennec Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 16.86% of the company’s stock.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
Read More
- Five stocks we like better than Fennec Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
